Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095762 | 0.76 | MEN1 (0.35) | MEN1KMT2ANCF1 | |
| SCHEMBL19923110 | 0.75 | MEN1 (0.34) | MEN1KMT2ANCF1 | |
| SCHEMBL18095740 | 0.74 | TRPC5 (0.36) | MAOB | |
| SCHEMBL19923116 | 0.73 | MEN1 (0.33) | MEN1KMT2ANCF1 | |
| SCHEMBL18095648 | 0.72 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL19923132 | 0.69 | MEN1 (0.35) | MEN1KMT2ANCF1KDM4EALDH1A1 | |
| SCHEMBL21505363 | 0.68 | TRIM24 (0.46) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL19923122 | 0.67 | FYN (0.41) | — | |
| SCHEMBL19923091 | 0.67 | KDM4E (0.36) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL19923162 | 0.66 | HTR1A (0.42) | MEN1KMT2ANCF1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663285-B1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-3663285-B1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| CN-107667092-B | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | 诺华股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210130323-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130323-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3663285-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3663285-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
| EP-3274344-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016151499-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | FGFR4, FGFR1, FGFR2 | MEN1 476/4885KMT2A 2239/4885NCF1 888/4885 |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | MEN1 2313/4885KMT2A 1228/4885NCF1 946/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | MEN1 2140/4885KMT2A 1321/4885NCF1 887/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | MEN1 2140/4885KMT2A 1321/4885NCF1 887/4885 |
| US-20210130323-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR4, FGFR1, FGFR2 | MEN1 476/4885KMT2A 2239/4885NCF1 888/4885 |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | MEN1 2140/4885KMT2A 1321/4885NCF1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.